NCT05800366View on ClinicalTrials.gov

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 6, 2023

Primary Completion Date

September 15, 2026

Study Completion Date

September 15, 2029

Conditions
LymphomaLymphoma, Large B-Cell, Diffuse
Interventions
DRUG

Glofitamab

human IgG1-bispecific antibody, via IV infusion

DRUG

Polatuzumab

an antibody drug conjugate (ADC) that contains a humanized IgG1 anti-human CD79b monoclonal antibody, via IV infusion

DRUG

Rituximab

Per standard care, via IV infusion

DRUG

Doxorubicin Hydrochloride

Per standard care, via IV infusion

DRUG

Cyclophosphamide

Per standard care, via IV infusion

DRUG

Prednisone

Per standard care, orally

Trial Locations (3)

33136

University of Miami Sylvester Cancer Center, Miami

02215

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Jennifer Crombie, MD

OTHER